GPRC5B protects osteoarthritis by regulation of autophagy signaling
Acta Pharmaceutica Sinica B · 2023-07 · 13 (7) · 2976-2989
DOI: 10.1016/j.apsb.2023.05.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-07. Verfasst von Liang He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai 201613, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Shanghai Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoarthritis (OA) is one of the most common chronic diseases in the world. However, current treatment modalities mainly relieve pain and inhibit cartilage degradation, but do not promote cartilage regeneration. In this study, we show that G protein-coupled receptor class C group 5 member B (GPRC5B), an orphan G-protein-couple receptor, not only inhibits cartilage degradation, but also increases cartilage regeneration and thereby is protective against OA. We observed that Gprc5b deficient chondrocytes had an upregulation of cartilage catabolic gene expression, along with downregulation of anabolic genes in vitro. Furthermore, mice deficient in Gprc5b displayed a more severe OA phenotype in the destabilization of the medial meniscus (DMM) induced OA mouse model, with upregulation of cartilage catabolic factors and downregulation of anabolic factors, consistent with our in vitro findings. Overexpression of Gprc5b by lentiviral vectors alleviated the cartilage degeneration in DMM-induced OA mouse model by inhibiting cartilage degradation and promoting regeneration. We also assessed the molecular mechanisms downstream of Gprc5b that may mediate these observed effects and identify the role of protein kinase B (AKT)-mammalian target of rapamycin (mTOR)-autophagy signaling pathway. Thus, we demonstrate an integral role of GPRC5B in OA pathogenesis, and activation of GPRC5B has the potential in preventing the progression of OA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai 201613, China.
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
- Department of Oncology and Metabolism, the Medical School, the University of Sheffield, Sheffield S10 2TN, UK.
- Department of Orthopedics, Tongji Hospital, Tongji University School of Medicine, Shanghai 200092, China.
Förderung
- Fundamental Research Funds for the Central Universities
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- East China Normal University
- National Key Research and Development Program of China
Zitieren
APA
He, L., Xu, Z., Niu, X., Li, R., Wang, F., You, Y., Gao, J., Zhao, L., Shah, K. M., Fan, J., Liu, M., & Luo, J. (2023). GPRC5B protects osteoarthritis by regulation of autophagy signaling. Acta Pharmaceutica Sinica B, 13(7), 2976-2989. https://doi.org/10.1016/j.apsb.2023.05.014
Vancouver
He L, Xu Z, Niu X, Li R, Wang F, You Y, et al. GPRC5B protects osteoarthritis by regulation of autophagy signaling. Acta Pharmaceutica Sinica B. 2023;13(7):2976-2989. doi:10.1016/j.apsb.2023.05.014
BibTeX
@article{He2023,
author = {He, Liang and Xu, Ziwei and Niu, Xin and Li, Rong and Wang, Fanhua and You, Yu and Gao, Jingduo and Zhao, Lei and Shah, Karan M and Fan, Jian and Liu, Mingyao and Luo, Jian},
title = {GPRC5B protects osteoarthritis by regulation of autophagy signaling},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {7},
pages = {2976--2989},
doi = {10.1016/j.apsb.2023.05.014}
}
EUVIMED